Nadia Tian, Co-founder of Bridge Point Capital, was invited to the Art Basel Miami Beach 2019 event from December 5th to 8th.
Art Basel Miami is the most comprehensive and sophisticated contemporary art exhibition in North America, showcasing art pieces created by over 4,000 talented artists from 35 countries and 268 galleries. Miami has been holding this annual art festival since 2002 as a sister fair of the original Art Basel founded in Switzerland in 1970. The event this year was divided into several sectors with distinctive styles: Galleries, Nova, Positions, Edition, Kabinett, Survey, Meridians and Magazines. Art Basel week is not limited to the event hosted in the main convention center – satellite fairs, glittering parties and world-class street arts have made Miami an attractive destination for art lovers.
The prices of art have surged as the global economy continues to grow. Artworks are becoming more attractive to investors as a supplement to traditional investment categories, such as stocks or real estates, and this is not only happening in the west – China’s artworks market, not surprisingly, tops the world in terms of growth in the past decade. At the same time, family offices, as perennial active players in the art space, contribute a huge unmet demand for art galleries and collections.
“Aside from seeking better investment opportunities for family offices, Bridge Point Capital also values the respect for the family culture.” said Nadia Tian, “Art collections hold indispensable value for family offices either as a part of the asset collection or a symbol of the family culture. Attending the Art Basel Miami Beach was important to Bridge Point Capital. We envision part of our mission to serve family offices and high net-worth individuals who are interested in art exhibitions and collections. We look forward to providing solutions for our clients in the aspects of family wealth preservation and appreciation, intergenerational transitions, and maintaining long-lasting corporate prosperity.”
Bridge Point Capital is a private equity firm based in New York with a focus on U.S.-China cross-border investment. We invest in disruptive late-stage healthcare companies that can benefit from penetrating the vast, yet unexplored, Chinese healthcare market. We aim to leverage our expertise in both healthcare and capital markets to provide the best investment platform we possibly can for our investors.